ClinicalTrials.gg
RecruitingNCT07414212NADALS-001-ALSUpdated Feb 17, 2026

Evaluation of the Combined Therapy of EH-301 and N-acetylcysteine Together With Riluzole in Amyotrophic Lateral Sclerosis (ALS)

A Phase 1/2 interventional study of Acetylcysteine and EH301 in Amyotrophic Lateral Sclerosis, sponsored by Biogipuzkoa Health Research Institute. Recruiting at 1 site in Spain. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-02-17.

Sponsored by Biogipuzkoa Health Research Institute · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 56 studies in Amyotrophic Lateral Sclerosis with a site in Spain — 11 open to participants now, 16 under way, 5 of them phase 3. Amyotrophic Lateral Sclerosis · Spain.

Planned enrollment
32nd of 51
90 · median 227
Started
2025
with 3 others
Phase 1/2
4 of 56
1 open now
Primary completion
2026-11
later than 6 of 15 live
Registered
52nd of 56
by date

Among the 56 studies in Amyotrophic Lateral Sclerosis with a site in Spain, this one is the 32nd largest by planned enrollment of the 51 interventional ones that give a count, is one of 4 that started in 2025, is one of 4 in phase 1/2, reaches primary completion later than 6 of the 15 other live ones, and was the 52nd registered.

Amyotrophic Lateral Sclerosis

981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

11 of the 56 studies in Amyotrophic Lateral Sclerosis with a site in Spain are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies in Amyotrophic Lateral Sclerosis with a site in Spain, or all of them as a file.
02

Study summary

This study is designed to evaluate whether a combination of N-acetylcysteine (NAC) and EH-301 can slow down or improve symptoms of amyotrophic lateral sclerosis (ALS). Researchers will assess changes in disease progression using the ALS Functional Rating Scale-Revised (ALSFRS-R), a standard tool for measuring daily functioning in people with ALS.

The main question is whether taking NAC together with EH-301 can prevent symptom worsening and possibly improve existing ALS symptoms.

Participants will be randomly assigned to receive either the active combination (NAC + EH-301) or matching placebos for 6 months. During this period, they will attend regular clinic visits for evaluations, tests, and safety monitoring.

After completing the initial 6-month phase, all participants may choose to join a 6-month open-label extension, where everyone receives the active treatment regardless of their original group.

03

Conditions studied

  • Amyotrophic Lateral Sclerosis

Keywords

  • Amyotrophic Lateral Sclerosis
  • Acetylcysteine
  • EH301
  • ALSFRS-R
  • ALS
  • NAC
  • Hospital Universitario Donostia
  • Biogipuzkoa
  • Adolfo López de Munain
  • NADALS-001-ALS-2021
  • Open Label Extension
  • NADALS
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients diagnosed with ALS according to the Gold Coast criteria;
  2. Disease duration ≤ 18 months;
  3. Men and women aged 18 to 75 years;
  4. Total ALSFRS-R score ≥ 30 for all 12 categories;
  5. Forced vital capacity (FVC) ≥70%;
  6. The participant must receive treatment with Riluzole (50 mg twice daily) for ≥30 days prior to Day 1 (Visit 2) and is expected to remain on that dose until the final study visit.
  7. Willingness and ability of the patient to comply with the requirements of the protocol during the study;
  8. Sign written prior to any study-related procedure;
  9. Acceptance by women to use at least one highly effective method of during the study 30 days prior to taking the nutraceutical and drug and throughout the study. The following are considered highly effective contraceptive methods:

    • Combined hormonal methods (oral, patches, injectables, or implants).
    • Hormonal or copper intrauterine devices (IUDs).
    • Previous surgical sterilization (bilateral tubal ligation).
    • Total sexual abstinence when consistent with the patient's usual lifestyle.
  10. Acceptance by men included in the study of the use of condoms in combination with an effective contraceptive method used by their female partner of childbearing age during treatment.

Exclusion criteria

Exclusion Criteria:

  1. Presence of other neurodegenerative diseases;
  2. Significant cognitive impairment and/or dementia;
  3. Any psychiatric illness that could interfere with the study;
  4. Use of dietary supplements with high doses of vitamin B3 in the 30 days prior to inclusion in the study;
  5. Severe heart disease;
  6. Moderate to severe lung disease, such as emphysema, stage III-IV ;
  7. Uncontrolled chronic asthma;
  8. Active cancer;
  9. Any metabolic, neoplastic, physically or mentally debilitating disease that could put the subject at risk or interfere with the study results;
  10. Genetically confirmed mitochondrial disease;
  11. Tracheostomized and/or gastrostomized patients;
  12. Participation in any clinical trial with an product within 30 days or five half-lives of the previous agent, whichever is longer, prior to dosing;
  13. Any laboratory abnormality that could directly affect compliance or safety;
  14. Allergy to NAC or any , either in the investigational drug or in the EH301 nutraceutical;
  15. Patients with a short in the investigator's judgment.
  16. [Women only] Pregnancy or breastfeeding for women of (i.e., \<2 years or not surgically sterile);
  17. The participant is unwilling to use highly effective during the study.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Acetylcysteine + EH301

    Combination of 600 mg of NAC + 1800 mg of EH301 (1500 mg of NR + 300 mg of PTER) + 100 mg of Riluzole (standard treatment for both arms)

    Drug: Acetylcysteine · Dietary Supplement: EH301 · Drug: Riluzole

  • Placebo comparator
    Acetylcysteine Placebo + EH301 Placebo

    Combination of NAC placebo + EH301 placebo + 100 mg of Riluzole (standard treatment for both arms)

    Drug: Riluzole

Interventions

06

What researchers measure

Primary outcomes

  1. ALSFRS-R scale

    Change from baseline in the ALS Functional Rating Scale-Revised (ALSFRS-R) \[range from 0 to 48, being 48 normal function and 0 complete function loss\] to assess disease progression and evaluate the clinical efficacy and safety of the combination of NAC and EH301 during the randomized treatment period (24 weeks) and, for participants who enter the open-label extension, up to 48 weeks.

    Time frame: Up to 48 weeks

Secondary outcomes

  1. Muscle strength

    Muscle strength measured by hand dynamometry during the randomized treatment period (24 weeks) and, for participants who enter the open-label extension, up to 48 weeks.

    Time frame: Up to 48 weeks

  2. Ventilation-free survival

    Percentage of participants who remain alive without requiring tracheotomy or permanent invasive ventilation during the randomized period (24 weeks) or, for those who enter the open-label extension, up to 48 weeks.

    Time frame: Up to 48 weeks

  3. Quality of life (ALSAQ-40)

    Quality of life assessed using the ALSAQ-40 questionnaire \[range from 0 to 100, being 0 best health status and 100 worst health status\] during the randomized treatment period (24 weeks) and, for participants who enter the open-label extension, up to 48 weeks.

    Time frame: Up to 48 weeks

  4. Respiratory function (%FVC)

    Respiratory function measured as percent predicted forced vital capacity (%FVC) during the randomized treatment period (24 weeks) and, for participants who enter the open-label extension, up to 48 weeks.

    Time frame: Up to 48 weeks

  5. Time to gastrostomy

    Time from baseline to placement of gastrostomy tube (percutaneous endoscopic gastrostomy or radiologically inserted gastrostomy). Participants in the open-label extension are followed for events up to 48 weeks.

    Time frame: Up to 48 weeks

  6. Combined Assessment of Function and Survival (CAFS)

    Combined Assessment of Function and Survival (CAFS) score calculated using ALSFRS-R change and survival status \[no fixed numerical range; ranking score where higher values indicate better combined functional status and survival\] during the randomized treatment period (24 weeks) and, for participants who enter the open-label extension, up to 48 weeks.

    Time frame: Up to 48 weeks

  7. Neurofilament light chain (NfL) biomarker

    Neurofilament light chain (NfL) levels in serum and cerebrospinal fluid will be measured for biomarker assessment. Analyses will evaluate the change from baseline in NfL concentrations during the randomized treatment period (24 weeks) and, for participants who enter the open-label extension, up to 48 weeks.

    Time frame: Up to 48 weeks

  8. Serum lipidomic profile

    Serum lipidomic components will be measured for biomarker assessment. Analyses will evaluate the change from baseline in the serum lipidomic profile during the randomized treatment period (24 weeks) and, for participants who enter the open-label extension, up to 48 weeks.

    Time frame: Up to 48 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Related links

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Nov 2026, 12 months after the start.

Of 36 phase 1/2 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 57. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2026
First posted
Feb 17, 2026
StartActual
Nov 25, 2025
Primary completionEst.
Nov 25, 2026
CompletionEst.
Nov 25, 2027
Last update
Feb 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07414212
Lead sponsor
Biogipuzkoa Health Research Institute
Responsible party
Sponsor
First posted
Feb 17, 2026
Start date
Nov 25, 2025
Primary completion
Nov 25, 2026 (estimated)
Completion
Nov 25, 2027 (estimated)
Last update
Feb 17, 2026

Study contacts

Lara Alameda Calvo
Contact
lara.alamedacalvo@bio-gipuzkoa.eus
+34 943006140

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nicotinamide-beta-riboside · Pterostilbene

Start the discussion